A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
← catalyst calendarNCT07211633 · readout in 73 d
Sponsored by TG Therapeutics, Inc. (industry) · TGTX — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
360estimated
Sites
48
Countries
Bosnia and Herzegovina, Bulgaria, Croatia +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-09 | actual | When the study began enrolling |
| Primary completion | 2026-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsing Multiple Sclerosis
Interventions
- Biological: Ublituximab — also filed as TG-1101
- Biological: Ublituximab — also filed as TG-1101
Primary outcome
what the primary-completion date above is the date OFArea Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab
measured Up to Week 24
Permalink · TGTX's whole pipeline · Catalyst calendar · Every registered study · What changed